CD4 and myeloid sarcoma: Future studies with larger, longitudinally sampled cohorts will be critical to disentangle these effects and determine whether CSF CD4+ T cell profiles could serve as reliable markers for disease stage, relapse risk, or progression to more advanced MS phenotypes.